Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.31 |
| ▸ | EP300 | Q09472 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17234920 | 0.83 | CYP2C19 (0.36) | CYP2C19HCAR2HTTHSD17B10 | |
| SCHEMBL20053807 | 0.79 | HMOX1 (0.35) | CYP2C19HCAR2HTTHSD17B10PARP1 | |
| SCHEMBL17232654 | 0.78 | CYP2C19 (0.56) | CYP2C19HCAR2JAK2 | |
| SCHEMBL20053806 | 0.78 | CREBBP (0.50) | CREBBPEP300BRD4 | |
| SCHEMBL19297272 | 0.77 | CYP2C19 (0.51) | CYP2C19HCAR2JAK2 | |
| SCHEMBL13948699 | 0.77 | HCAR2 (0.44) | HCAR2HTTHSD17B10GAA | |
| SCHEMBL14048246 | 0.77 | HCAR2 (0.44) | HCAR2HTTHSD17B10GAA | |
| SCHEMBL19831875 | 0.77 | CREBBP (0.53) | HCAR2PARP1CREBBPEP300BRD4 | |
| SCHEMBL17229730 | 0.75 | CYP2C19 (0.57) | CYP2C19HCAR2HSD17B10GAAJAK2 | |
| SCHEMBL17221260 | 0.75 | CYP2C19 (0.62) | CYP2C19HSD17B10GAACREBBPBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10273243-B2 | 4-phenylpiperidines, their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10273243-B2 | 4-phenylpiperidines, their preparation and use | HTR3C, HRH4, CYP4F3 | CYP2C19 117/4885HCAR2 983/4885HTT 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.